Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Study Programme

Author： SWEDBERG K.   PFEFFER M.   GRANGER G. B.   McMURRAY J.   YUSUF S.  

Publisher： Informa Healthcare

ISSN： 0803-7051

Source： Blood Pressure, Vol.9, Iss.1, 2000-05, pp. : 60-60

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Kardioprotektion durch Candesartan bei Herzinsuffizienz: CHARM-overall-Teilauswertung (Candesartan in heart failure assessment of reduction in mortality and morbidity)

By Tschöpe C.   Schultheiss H.  

Der Internist, Vol. 47, Iss. 10, 2006-10 ,pp. : 1084-1086

Springer Publishing Company

Access to resources Recommend Favorite

Current and future uses of candesartan in the treatment of heart failure

By McKelvie Robert S  

Future Cardiology, Vol. 2, Iss. 4, 2006-07 ,pp. : 391-402

Future Medicine

Access to resources Recommend Favorite

The Effects of Beta Blockers on Morbidity and Mortality in Heart Failure: Special Issue: An Overview of Beta-Blockers and Heart Failure (Guest Editor: Syed M. Jafri)

By Jafri Syed M.  

Heart Failure Reviews, Vol. 9, Iss. 2, 2004-04 ,pp. : 115-121

Springer Publishing Company

Access to resources Recommend Favorite

Health Literacy and Mortality: A Cohort Study of Patients Hospitalized for Acute Heart Failure

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 4, Iss. 6, 2015-06 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Health Literacy and Mortality: A Cohort Study of Patients Hospitalized for Acute Heart Failure

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 4, Iss. 5, 2015-05 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite